OBP-2011 is a compound that specifically inhibits the replication of the novel coronavirus SARS-CoV-2 causing COVID-19.
We concluded a joint research agreement with Kagoshima University in 2006 and have conducted drug discovery research. As a result, we have identified the OBP-2011 that have an efficacy to specifically inhibit replication on SARS-CoV-2 virus. In addition, we confirmed the OBP-2011 was equally effective to or even better than the wild type COVID-19.
Various types of vaccines against SARS-CoV-2 virus have been developed around the world, and its vaccination has started in Japan as well. However, SARS-CoV-2 virus can be easily mutated and it may be difficult to control the global pandemic only with vaccines. Thus, we are making comprehensive effort to develop OBP-2011 that can be administered orally with a goal of completely suppressing the replication of SARS-CoV-2 virus.
SARS-Cov-2 virus infection
Preclinical study in progress
- For progress of development, refer to "Outline of Our Pipeline: Progress chart of pipeline.
- For details, refer to "Research and Development Activities" in the latest financial statements.